Literature DB >> 33159673

Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer.

Bartosz Mateusz Gąsiorkiewicz1, Paulina Koczurkiewicz-Adamczyk2, Kamil Piska2, Elżbieta Pękala2.   

Abstract

Although cisplatin is one of the most common antineoplastic drug, its successful utilisation in cancer treatment is limited by the drug resistance. Multiple attempts have been made to find potential cisplatin chemosensitisers which would overcome cancer cells resistance thus improving antineoplastic efficacy. Autophagy modulation has become an important area of interest regarding the aforementioned topic. Autophagy is a highly conservative cellular self-digestive process implicated in response to multiple environmental stressors. The high basal level of autophagy is a common phenomenon in cisplatin-resistant cancer cells which is thought to grant survival benefit. However current evidence supports the role of autophagy in either promoting or limiting carcinogenesis depending on the context. This encourages the search of substances modulating the process to alleviate cisplatin resistance. Such a strategy encompasses not only simple autophagy inhibition but also harnessing the process to induce autophagy-dependent cell death. In this paper, we briefly describe the mechanism of cisplatin resistance with a special emphasis on autophagy and we give an extensive literature review of potential substances with cisplatin chemosensitising properties related to autophagy modulation.

Entities:  

Keywords:  Autophagy; Cancer resistance; Cisplatin; Combination therapy

Mesh:

Substances:

Year:  2020        PMID: 33159673      PMCID: PMC7960624          DOI: 10.1007/s10637-020-01032-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  109 in total

1.  Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin.

Authors:  Nasma D Eljack; Ho-Yu M Ma; Janine Drucker; Clara Shen; Trevor W Hambley; Elizabeth J New; Thomas Friedrich; Ronald J Clarke
Journal:  Metallomics       Date:  2014-11       Impact factor: 4.526

2.  Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.

Authors:  Toshiyuki Matsunaga; Aki Hojo; Yumi Yamane; Satoshi Endo; Ossama El-Kabbani; Akira Hara
Journal:  Chem Biol Interact       Date:  2012-11-16       Impact factor: 5.192

3.  Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.

Authors:  Roohangiz Safaei; Kuniyuki Katano; Barrett J Larson; Goli Samimi; Alison K Holzer; Wiltrud Naerdemann; Mika Tomioka; Murray Goodman; Stephen B Howell
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

Review 4.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

Review 5.  Cisplatin: The first metal based anticancer drug.

Authors:  Sumit Ghosh
Journal:  Bioorg Chem       Date:  2019-04-11       Impact factor: 5.275

Review 6.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

Review 7.  Platinum resistance: the role of DNA repair pathways.

Authors:  Lainie P Martin; Thomas C Hamilton; Russell J Schilder
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  After surviving cancer, what about late life effects of the cure?

Authors:  Julie Nonnekens; Jan Hj Hoeijmakers
Journal:  EMBO Mol Med       Date:  2017-01       Impact factor: 12.137

Review 9.  Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

Authors:  Kinrin Yamanaka; Nimrat Chatterjee; Michael T Hemann; Graham C Walker
Journal:  PLoS Genet       Date:  2017-08-17       Impact factor: 5.917

10.  Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy.

Authors:  Tomaz Makovec
Journal:  Radiol Oncol       Date:  2019-03-28       Impact factor: 2.991

View more
  12 in total

1.  NEDD9 Restrains dsDNA Damage Response during Non-Small Cell Lung Cancer (NSCLC) Progression.

Authors:  Mariya Tikhomirova; Iuliia Topchu; Aleksandra Mazitova; Vitaly Barmin; Ekaterina Ratner; Alexey Sabirov; Zinaida Abramova; Alexander Y Deneka
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

2.  A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition.

Authors:  Penghui Hu; Kaman So; Hongjie Chen; Qimou Lin; Meng Xu; Yiguang Lin
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

3.  Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.

Authors:  Lena Berning; David Schlütermann; Annabelle Friedrich; Niklas Berleth; Yadong Sun; Wenxian Wu; María José Mendiburo; Jana Deitersen; Hannah U C Brass; Margaretha A Skowron; Michèle J Hoffmann; Günter Niegisch; Jörg Pietruszka; Björn Stork
Journal:  Molecules       Date:  2021-02-27       Impact factor: 4.411

Review 4.  Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies.

Authors:  Sepideh Mirzaei; Kiavash Hushmandi; Amirhossein Zabolian; Hossein Saleki; Seyed Mohammad Reza Torabi; Adnan Ranjbar; SeyedHesam SeyedSaleh; Seyed Omid Sharifzadeh; Haroon Khan; Milad Ashrafizadeh; Ali Zarrabi; Kwang-Seok Ahn
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

5.  A Novel Autophagy-Related Prognostic Risk Model and a Nomogram for Survival Prediction of Oral Cancer Patients.

Authors:  Hongjun Fei; Xiongming Chen
Journal:  Biomed Res Int       Date:  2022-01-06       Impact factor: 3.411

6.  Effects of cisplatin on mitochondrial function and autophagy-related proteins in skeletal muscle of rats.

Authors:  Dae Yun Seo; Jun Hyun Bae; Didi Zhang; Wook Song; Hyo-Bum Kwak; Jun-Won Heo; Su-Jeen Jung; Hyeong Rok Yun; Tae Nyun Kim; Sang Ho Lee; Amy Hyein Kim; Dae Hoon Jeong; Hyoung Kyu Kim; Jin Han
Journal:  BMB Rep       Date:  2021-11       Impact factor: 4.778

7.  Escape From Cisplatin-Induced Senescence of Hypoxic Lung Cancer Cells Can Be Overcome by Hydroxychloroquine.

Authors:  Aleksandra Olszewska; Agata Borkowska; Monika Granica; Justyna Karolczak; Bartosz Zglinicki; Claudine Kieda; Halina Was
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

8.  Combinative treatment of Curdione and docetaxel triggers reactive oxygen species (ROS)-mediated intrinsic apoptosis of triple-negative breast cancer cells.

Authors:  Changcheng Wang; Jia Guo; Zeng'An Wu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Combination Chemotherapy with Cisplatin and Chloroquine: Effect of Encapsulation in Micelles Formed by Self-Assembling Hybrid Dendritic-Linear-Dendritic Block Copolymers.

Authors:  Rebeca González-Pastor; Alexandre Lancelot; Violeta Morcuende-Ventura; María San Anselmo; Teresa Sierra; José L Serrano; Pilar Martin-Duque
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

Review 10.  Is Autophagy Always a Barrier to Cisplatin Therapy?

Authors:  Jingwen Xu; David A Gewirtz
Journal:  Biomolecules       Date:  2022-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.